Pronostic and predictive factors in lung cancer;Facteurs pronostiques et prédictifs des cancers bronchiques

Bulletin du Cancer

Volumn 96, Issue 4, 2009, Pages 391-404

  Marijon, H ^a   Bouyon, A ^a   Vignot, S ^b   Besse, B ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Chemotherapy; Molecular targeted therapies; Non small cell lung cancer; Predictive factors; Prognostic factors; Small cell lung cancer

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; BIOLOGICAL MARKER; BRCA1 PROTEIN; CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEFITINIB; GEMCITABINE; METALLOPROTEINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; NAVELBINE; PACLITAXEL; PLACEBO; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; RAS PROTEIN; RIBONUCLEOTIDE REDUCTASE; SORAFENIB; SUNITINIB; THALIDOMIDE; TRANSCRIPTOME; VANDETANIB;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER STAGING; CELL CYCLE REGULATION; CLINICAL TRIAL; CYTOTOXICITY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; HUMAN; LUNG CANCER; LUNG SMALL CELL CANCER; LYMPHADENOPATHY; METASTASIS; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SCORING SYSTEM; SEX DIFFERENCE; SIGNAL TRANSDUCTION; TOBACCO DEPENDENCE; TUMOR VOLUME;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMALL CELL LUNG CARCINOMA; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 66349131703     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2009.0779     Document Type: Review

References (55)

1. Hill C, Doyon F. La fréquence des cancers en France : mortalité en 2003, évolution depuis 1968 et cancers de l'enfant. Bull Cancer 2007 ; 94(1) : 7-13.
2. Besse B, Depierre A, Guillo S, Séblain-El Guerche C, Douillard JY, Giniès A, et al. Standards, Options et Recommandations pour le traitement périopératoire des patients atteints d'un cancer bronchique non à petites cellules résécable d'emblée, opérables (mise à jour), rapport abrégé. Bull Cancer 2007 ; 94(10) : 887-896 (Pubitemid 350131960)
3. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 2002 ; 122(3) : 1037-1057
4. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997 ; 111(6) : 1710-1717 (Pubitemid 27260107)
5. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumors. J Thorac Oncol 2007 ; 2(8) : 706-714 (Pubitemid 47357522)
6. Ou SH, Zell JA, Ziogas A, Anton-Culver H. Prognostic factors for survival of stage I non-small cell lung cancer patients: a populationbased analysis of 19,702 stage I patients in the California Cancer Registry from 1989 to 2003. Cancer 2007 ; 110(7) : 1532-1541
7. Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 1995 ; 60(3) : 615-622 (discussion 22-3).
8. Gajra A, Newman N, Gamble GP, Kohman LJ, Graziano SL. Effect of number of lymph nodes sampled on outcome in patients with stage I non-small-cell lung cancer. J Clin Oncol 2003 ; 21(6) : 1029-1034 (Pubitemid 46594131)
9. Caldarella A, Crocetti E, Comin CE, Janni A, Pegna AL, Paci E. Prognostic variability among non-small cell lung cancer patients with pathologic N1 lymph node involvement. Epidemiological figures with strong clinical implications. Cancer 2006 ; 107(4) : 793-798
10. Riquet M, Assouad J, Bagan P, Foucault C, Le Pimpec Barthes F, Dujon A, et al. Skip mediastinal lymph node metastasis and lung cancer: a particular N2 subgroup with a better prognosis. Ann Thorac Surg 2005 ; 79(1) : 225-233 (Pubitemid 40037476)
11. Andre F, Grunenwald D, Pignon JP, Dujon A, Pujol JL, Brichon PY, et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a sub-classification and implications. J Clin Oncol 2000 ; 18(16) : 2981-2989 (Pubitemid 30644122)
12. Postmus PE, Brambilla E, Chansky K, Crowley J, Goldstraw P, Patz Jr. EF, et al. The IASLC Lung Cancer Staging Project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer. J Thorac Oncol 2007 ; 2(8) : 686-693 (Pubitemid 47357520)
13. Birim O, Kappetein AP, van Klaveren RJ, Bogers AJ. Prognostic factors in non-small cell lung cancer surgery. Eur J Surg Oncol 2006 ; 32(1) : 12-23. (Pubitemid 43103982)
14. Sakao Y, Miyamoto H, Sakuraba M, Oh T, Shiomi K, Sonobe S, et al. Prognostic significance of a histologic subtype in small adenocarcinoma of the lung: the impact of non-bronchioloalveolar carcinoma components. Ann Thorac Surg 2007 ; 83(1) : 209-214 (Pubitemid 44917878)
15. Martin LW, Correa AM, Ordonez NG, Roth JA, Swisher SG, Vaporciyan AA, et al. Sarcomatoid carcinoma of the lung: a predictor of poor prognosis. Ann Thorac Surg 2007 ; 84(3) : 973-980 (Pubitemid 47285034)
16. Gabor S, Renner H, Popper H, Anegg U, Sankin O, Matzi V, et al. Invasion of blood vessels as significant prognostic factor in radically resected T1-3N0M0 non-small-cell lung cancer. Eur J Cardiothorac Surg 2004 ; 25(3) : 439-442 (Pubitemid 38340584)
17. Trivella M, Pezzella F, Pastorino U, Harris AL, Altman DG. Microvessel density as a prognostic factor in non-small-cell lung carcinoma: a meta-analysis of individual patient data. Lancet Oncol 2007 ; 8(6) : 488-499 (Pubitemid 46805904)
18. Cerfolio RJ, Bryant AS, Scott E, Sharma M, Robert F, Spencer SA, et al. Women with pathologic stage I, II, and III non-small cell lung cancer have better survival than men. Chest 2006 ; 130(6) : 1796-1802
19. Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P. Smoking and lung cancer survival: the role of comorbidity and treatment. Chest 2004 ; 125(1) : 27-37. (Pubitemid 38114560)
20. Yovino S, Kwok Y, Krasna M, Bangalore M, Suntharalingam M. An association between preoperative anaemia and decreased survival in early-stage non-small-cell lung cancer patients treated with surgery alone. Int J Radiat Oncol Biol Phys 2005 ; 62(5) : 1438-1443 (Pubitemid 40982067)
21. Depierre A, Lagrange JL, Theobald S, Astoul P, Baldeyrou P, Bardet E, et al. Standards, Options et Recommandations 2000 pour la prise en charge des patients atteints d'un cancer bronchopulmonaire non à petites cellules (rapport abrégé). Bull Cancer 2003 ; 90(2) : 151-166
22. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006 ; 355(10) : 983-991 (Pubitemid 44343542)
23. Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007 ; 356(8) : 800-808 (Pubitemid 46294612)
24. Tsao MS, Aviel-Ronen S, Ding K, Lau D, Liu N, Sakurada A, et al. Prognostic and predictive importance of p53 and ras for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol 2007 ; 25(33) : 5240-5247 (Pubitemid 350232256)
25. Filipits M, Pirker R, Dunant A, Lantuejoul S, Schmid K, Huynh A, et al. Cell cycle regulators and outcome of adjuvant cisplatinbased chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program. J Clin Oncol 2007 ; 25(19) : 2735-2740 (Pubitemid 47123181)
26. Hirsch FR, Varella-Garcia M, Bunn Jr. PA, Di Maria MV, Veve R, Bremmes RM, et al. Epidermal growth factor receptor in nonsmall- cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003 ; 21(20) : 3798-3807 (Pubitemid 46606235)
27. Aviel-Ronen S, Blackhall FH, Shepherd FA, Tsao MS. K-ras mutations in non-small-cell lung carcinoma: a review. Clin Lung Cancer 2006 ; 8(1) : 30-38 (Pubitemid 44336241)
28. Potti A, Mukherjee S, Petersen R, Dressman HK, Bild A, Koontz J, et al. A genomic strategy to refine prognosis in early-stage nonsmall- cell lung cancer. N Engl J Med 2006 ; 355(6) : 570-580 (Pubitemid 44200650)
29. Berghmans T, Dusart M, Paesmans M, Hossein-Foucher C, Buvat I, Castaigne C, et al. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol 2008 ; 3(1) : 6-12.
30. Weinmann M, Jeremic B, Toomes H, Friedel G, Bamberg M. Treatment of lung cancer in the elderly. Part I: non-small cell lung cancer. Lung Cancer 2003 ; 39(3) : 233-253
31. Wakelee HA, Wang W, Schiller JH, Langer CJ, Sandler AB, Belani CP, et al. Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594. J Thorac Oncol 2006 ; 1(5) : 441-446 (Pubitemid 47181421)
32. Bossard N, Velten M, Remontet L, Belot A, Maarouf N, Bouvier AM, et al. Survival of cancer patients in France: a population-based study from The Association of the French Cancer Registries (FRANCIM). Eur J Cancer 2007 ; 43(1) : 149-160 (Pubitemid 46054480)
33. Meert AP, Martin B, Delmotte P, Berghmans T, Lafitte JJ, Mascaux C, et al. The role of EGFR expression on patient survival in lung cancer: a systematic review with meta-analysis. Eur Respir J 2002 ; 20(4) : 975-981 (Pubitemid 35175137)
34. Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, et al. Mutations in the epidermal growth factor receptor and in K-ras are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005 ; 23(25) : 5900-5909 (Pubitemid 46300206)
35. Lee JS, Scott CB, Komaki R, Ettinger DS, Sause WT. Impact of institutional experience on survival outcome of patients undergoing combined chemoradiation therapy for inoperable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002 ; 52(2) : 362-370 (Pubitemid 34170843)
36. Cobo M, Isla D, Massuti B, Montes A, Sanchez JM, Provencio M, et al. Customizing cisplatin-based on quantitative excision repairs cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 2007 ; 25(19) : 2747-2754 (Pubitemid 47123183)
37. Rosell R, Danenberg KD, Alberola V, Bepler G, Sanchez JJ, Camps C, et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced nonsmall cell lung cancer patients. Clin Cancer Res 2004 ; 10(4) : 1318-1325 (Pubitemid 38365223)
38. Rosell R, Cuello M, Cecere F, Santarpia M, Reguart N, Felip E, et al. Usefulness of predictive tests for cancer treatment. Bull Cancer 2006 ; 93(8) : E101-8.
39. Sequist LV. Second-generation epidermal growth factor receptor tyrosine-kinase inhibitors in non-small cell lung cancer. Oncologist 2007 ; 12(3) : 325-330 (Pubitemid 46556799)
40. Cappuzzo F, Ligorio C, Toschi L, Rossi E, Trisolini R, Paioli D, et al. EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). J Thorac Oncol 2007 ; 2(5) : 423-429 (Pubitemid 47181697)
41. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, et al. Vinorelbine plus cisplatin versus observation in resected nonsmall- cell lung cancer. N Engl J Med 2005 ; 352(25) : 2589-2597 (Pubitemid 41007845)
42. Seve P, Lai R, Ding K, Winton T, Butts C, Mackey J, et al. Class III beta-tubulin expression and benefit from adjuvant cisplatinvinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10. Clin Cancer Res 2007 ; 13(3) : 994-999 (Pubitemid 46340378)
43. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, et al. Erlotinib in lung cancer: molecular and clinical predictors of outcome. N Engl J Med 2005 ; 353(2) : 133-144 (Pubitemid 41058345)
44. Shepherd F, Sakurada A, da Cunha Santos G, Zhu CQ, Seymour L. Updated molecular analyses of exons 19 and 21 of the epidermal growth factor receptor (EGFR) gene and codons 12 and 13 of the Kras gene in non-small cell lung cancer (NSCLC) patients treated with erlotinib in National Cancer Institute of Cancer. J Clin Oncol 2007 ; 25(Suppl 18S) : 7571 (ASCO Annual Meeting Proceedings Part I).
45. Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in nonsmall- cell lung cancer. J Clin Oncol 2007 ; 25(5) : 587-595 (Pubitemid 350002967)
46. Douillard JY, Kim E, Hirsch V, Mok T, Socinski M, Gervais R. Gefitinib (Iressa®) versus docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer pretreated with platinum-based chemotherapy: a randomized, open-label phase III study (INTEREST): PRS-02. J Thorac Oncol 2007 ; 2(8 Suppl 4) : S305-S3S6.
47. Cappuzzo F, Ligorio C, Janne PA, Toschi L, Rossi E, Trisolini R, et al. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. J Clin Oncol 2007 ; 25(16) : 2248-2255 (Pubitemid 46954651)
48. Besse B, Ropert S, Soria JC. Targeted therapies in lung cancer. Ann Oncol 2007 ; 18(Suppl 9) : ix135-ix142.
49. Gatzemeier U, Blumenschein G, Fosella F, Simantov R, Elting J, Bigwood D. Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma. J Clin Oncol 2006 ; 24 (Suppl 18S) : 7002 (ASCO Annual Meeting Proceedings Part I).
50. Lally BE, Urbanic JJ, Blackstock AW, Miller AA, Perry MC. Small cell lung cancer: have we made any progress over the last 25 years? Oncologist 2007 ; 12(9) : 1096-1104
51. Paesmans M, Sculier JP, Lecomte J, Thiriaux J, Libert P, Sergysels R, et al. Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years. Cancer 2000 ; 89(3) : 523-533 (Pubitemid 30640099)
52. Cerny T, Blair V, Anderson H, Bramwell V, Thatcher N. Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. Int J Cancer 1987 ; 39(2) : 146-149 (Pubitemid 17015271)
53. Board RE, Thatcher N, Lorigan P. Novel therapies for the treatment of small-cell lung cancer: a time for cautious optimism? Drugs 2006 ; 66(15) : 1919-1931
54. Lee HW, Han JH, Kim JH, Lee MH, Jeong SH, Kang SY, et al. Expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with small cell lung cancer. Lung Cancer 2008 ; 59(1) : 95-104.
55. Pao W, Ladanyi M, Miller VA. Erlotinib in lung cancer. New Engl J Med 2005 ; 353(16) : 1739-1741 (author reply-41).